Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CFO Alexis Desieno sold 7,451 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $7.95, for a total transaction of $59,235.45. Following the completion of the transaction, the chief financial officer now owns 6,898 shares in the company, valued at $54,839.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Cardlytics Stock Performance
Shares of NASDAQ CDLX traded down $0.25 during mid-day trading on Tuesday, hitting $7.83. 750,273 shares of the company were exchanged, compared to its average volume of 1,368,857. The company has a quick ratio of 2.13, a current ratio of 2.13 and a debt-to-equity ratio of 1.30. The stock has a 50 day simple moving average of $9.89 and a 200-day simple moving average of $9.56. Cardlytics, Inc. has a 1-year low of $5.69 and a 1-year high of $20.52. The firm has a market cap of $381.95 million, a price-to-earnings ratio of -1.77 and a beta of 1.65.
Cardlytics (NASDAQ:CDLX – Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.35) EPS for the quarter. Cardlytics had a negative net margin of 55.23% and a negative return on equity of 25.36%. The business had revenue of $67.61 million during the quarter. On average, sell-side analysts forecast that Cardlytics, Inc. will post -1.8 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on CDLX
Institutional Investors Weigh In On Cardlytics
A number of hedge funds and other institutional investors have recently bought and sold shares of CDLX. Kent Lake Capital LLC acquired a new position in shares of Cardlytics during the 1st quarter worth $3,622,000. Blackstone Inc. acquired a new position in shares of Cardlytics during the 1st quarter worth $2,029,000. Perbak Capital Partners LLP acquired a new position in shares of Cardlytics during the 1st quarter worth $2,348,000. Price T Rowe Associates Inc. MD increased its position in Cardlytics by 6.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after purchasing an additional 1,774 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in Cardlytics during the 1st quarter worth about $1,906,000. Institutional investors and hedge funds own 68.10% of the company’s stock.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Articles
- Five stocks we like better than Cardlytics
- What Do S&P 500 Stocks Tell Investors About the Market?
- RXO Shares Surge Following New Acquisition Deal
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Using the MarketBeat Dividend Tax Calculator
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.